1. Home
  2. BUJA vs MAIA Comparison

BUJA vs MAIA Comparison

Compare BUJA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BUJA
  • MAIA
  • Stock Information
  • Founded
  • BUJA 2022
  • MAIA 2018
  • Country
  • BUJA Malaysia
  • MAIA United States
  • Employees
  • BUJA N/A
  • MAIA N/A
  • Industry
  • BUJA Blank Checks
  • MAIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • BUJA Finance
  • MAIA Health Care
  • Exchange
  • BUJA Nasdaq
  • MAIA Nasdaq
  • Market Cap
  • BUJA N/A
  • MAIA 62.4M
  • IPO Year
  • BUJA 2023
  • MAIA 2022
  • Fundamental
  • Price
  • BUJA $10.96
  • MAIA $2.82
  • Analyst Decision
  • BUJA
  • MAIA
  • Analyst Count
  • BUJA 0
  • MAIA 0
  • Target Price
  • BUJA N/A
  • MAIA N/A
  • AVG Volume (30 Days)
  • BUJA 2.7K
  • MAIA 60.0K
  • Earning Date
  • BUJA 01-01-0001
  • MAIA 11-05-2024
  • Dividend Yield
  • BUJA N/A
  • MAIA N/A
  • EPS Growth
  • BUJA N/A
  • MAIA N/A
  • EPS
  • BUJA 0.29
  • MAIA N/A
  • Revenue
  • BUJA N/A
  • MAIA N/A
  • Revenue This Year
  • BUJA N/A
  • MAIA N/A
  • Revenue Next Year
  • BUJA N/A
  • MAIA N/A
  • P/E Ratio
  • BUJA $37.13
  • MAIA N/A
  • Revenue Growth
  • BUJA N/A
  • MAIA N/A
  • 52 Week Low
  • BUJA $10.30
  • MAIA $0.82
  • 52 Week High
  • BUJA $12.18
  • MAIA $5.99
  • Technical
  • Relative Strength Index (RSI)
  • BUJA 67.66
  • MAIA 50.98
  • Support Level
  • BUJA $10.85
  • MAIA $2.36
  • Resistance Level
  • BUJA $10.85
  • MAIA $2.72
  • Average True Range (ATR)
  • BUJA 0.00
  • MAIA 0.22
  • MACD
  • BUJA -0.00
  • MAIA 0.02
  • Stochastic Oscillator
  • BUJA 87.50
  • MAIA 72.28

About BUJA Bukit Jalil Global Acquisition 1 Ltd.

Bukit Jalil Global Acquisition 1 Ltd is a blank check company.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Share on Social Networks: